Barclays maintains Legend Biotech at Overweight, lowers price target to $61 from $68
Barclays kept Legend Biotech's rating at Overweight but reduced its price target to $61 from $68. The new target suggests a 198.9% upside from the Nov 10 close of $20.41, according to the bank.
How this was made

The 30-second read
Why it matters
The downgrade may trigger short-term selling pressure, but the Overweight stance leaves room for upside if new data emerges.
Market read
Analyst target cut on a microcap biotech can cause immediate price movement, offering a short-term trading signal.
What to watch
Potential pipeline milestones not reflected in the downgrade.
Background
Barclays maintains an Overweight rating but reduces its price target, a typical analyst action that can move small-cap stocks.
Market effects
May affect sentiment toward other biotech microcaps.
Limited to US biotech sector.
Low
Counterpoint
The target cut could be overdone if upcoming trial data exceeds expectations.
Key entities
- AnalystBarclays
Equity research firm issuing the rating and target change.
- CompanyLegend Biotech
US-listed biotech firm (ticker LGND).


